公开(公告)号：US20180246081A1

公开(公告)日：2018-08-30

申请号：US15964210

申请日：2018-04-27

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA

IPC分类号： G01N33/50 ,  A61K31/7052 ,  A01K67/027 ,  A61K45/00

CPC分类号： G01N33/5088 ,  A01K67/027 ,  A01K2207/25 ,  A01K2227/105 ,  A01K2267/035 ,  A61K31/7052 ,  A61K45/00 ,  G01N33/5082 ,  G01N2500/10 ,  G01N2800/162

摘要： A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

公开(公告)号：US09955675B2

公开(公告)日：2018-05-01

申请号：US14397091

申请日：2013-04-25

申请人： TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE ,  CHUGAI SEIYAKU KABUSHIKI KAISHA ,  PHOENIXBIO CO., LTD.

发明人： Michinori Kohara ,  Koichi Jishage ,  Yosuke Kawase ,  Chise Mukaidani ,  Hiroki Oshita ,  Satoko Hamamura

IPC分类号： A01K67/00 ,  A01K67/027 ,  C12N9/72 ,  C12N15/85 ,  C12N15/877 ,  G01N33/50

CPC分类号： A01K67/0275 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0337 ,  A01K2267/035 ,  C12N9/6462 ,  C12N15/8509 ,  C12N15/8775 ,  C12N2015/8581 ,  G01N33/5067 ,  G01N33/5088 ,  Y10T436/146666

摘要： The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of:(i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof;(ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo;(iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and(iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.

公开(公告)号：US09949465B2

公开(公告)日：2018-04-24

申请号：US14888398

申请日：2014-04-30

申请人： HYOGO COLLEGE OF MEDICINE ,  MIE UNIVERSITY

发明人： Kiyofumi Yamanishi ,  Hitoshi Mizutani ,  Yasutomo Imai ,  Tomohiro Yoshimoto ,  Kenji Nakanishi

IPC分类号： A01K67/027 ,  C07K14/54 ,  A61K49/00

CPC分类号： A01K67/0278 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0368 ,  A61K49/0008 ,  C07K14/54

摘要： The present invention provides a transgenic non-human mammal retaining, in a specifically expressible state, a DNA encoding IL-33 in the skin, and having one or more features selected from the group consisting of (1) spontaneous onset of dermatitis, (2) increase in the number of inflammatory cells, (3) increase in total IgE concentration, histamine concentration, cytokine concentration and/or chemokine concentration, and (4) increase in scratching time, under SPF (specific pathogen free) breeding conditions, as compared to a corresponding non-transgenic non-human mammal, and the like.

公开(公告)号：US09877981B2

公开(公告)日：2018-01-30

申请号：US14434573

申请日：2013-10-09

申请人： President and Fellows of Harvard College ,  NewSouth Innovations Pty Limited

发明人： David A. Sinclair ,  Ana P. Gomes ,  Lindsay Wu

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7064 ,  A61K38/45 ,  A61K48/00 ,  A61K31/706

CPC分类号： A61K31/7064 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A61K31/706 ,  A61K38/45 ,  A61K48/005 ,  C12Y204/02012 ,  C12Y207/07001

摘要： Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods.Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction.The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

公开(公告)号：US20170266322A1

公开(公告)日：2017-09-21

申请号：US15614597

申请日：2017-06-05

申请人： The J. David Gladstone Institutes, a testamentary established under the Will of J. David Glads

发明人： Katerina Akassoglou ,  Jae Kyu Ryu

IPC分类号： A61K49/00 ,  A01K67/027 ,  C07K14/75

CPC分类号： A61K49/0008 ,  A01K67/027 ,  A01K2207/10 ,  A01K2227/105 ,  A01K2267/0318 ,  A01K2267/035 ,  C07K14/75

摘要： The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegeneration in selected regions of interest in the CNS, and thus especially useful for testing the therapeutic efficacy of agents targeting neurodegeneration associated with aging, neurodegenerative diseases, autoimmunity and trauma (e.g., ischemia).

公开(公告)号：US20170196207A1

公开(公告)日：2017-07-13

申请号：US15314647

申请日：2015-06-03

申请人： Arturo SOLIS HERRERA, M.D., Ph.D.

发明人： Arturo SOLIS HERRERA, M.D., Ph.D.

IPC分类号： A01K67/027 ,  A61K49/00

CPC分类号： A01K67/027 ,  A01K2227/10 ,  A01K2267/035 ,  A61K31/03 ,  A61K31/05 ,  A61K49/0008

摘要： Methods of producing non-human animal models of corneal angiogenesis and corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal angiogenesis and corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal angiogenesis and corneal ectatic diseases.

公开(公告)号：US20170014486A1

公开(公告)日：2017-01-19

申请号：US15039982

申请日：2014-12-04

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： Mark A. HOON ,  Santosh K. MISHRA

IPC分类号： A61K38/22 ,  C12N15/113 ,  A61K47/48 ,  A61K38/17 ,  C07K16/26

CPC分类号： A61K38/22 ,  A01K67/0276 ,  A01K2217/052 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0393 ,  A61K38/164 ,  A61K38/1796 ,  A61K38/2242 ,  A61K45/06 ,  A61K47/62 ,  C07K16/26 ,  C12N15/1136 ,  C12N15/8509 ,  C12N2310/14 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2500/02

摘要： Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.

摘要翻译： 公开了治疗，减轻或预防哺乳动物瘙痒的方法，所述方法包括以有效治疗或预防哺乳动物瘙痒的量向哺乳动物施用至少一种利钠肽多肽（Nppb）封闭剂。 还公开了鉴定抑制Nppb活性的化合物的体外方法。

公开(公告)号：US20160120158A1

公开(公告)日：2016-05-05

申请号：US14930883

申请日：2015-11-03

申请人： The Johns Hopkins University

发明人： Hamid Rabb ,  Sanjeev Noel ,  Maria N. Martina-Lingua ,  Lorraine C. Racusen ,  Abdel Rahim Hamad ,  Samatha Bandapalle

IPC分类号： A01K67/027 ,  A61K35/17

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/035 ,  A61K35/17

摘要： The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject.

摘要翻译： 本发明涉及肾脏病学领域。 更具体地，本发明提供了用于研究和治疗急性肾损伤的组合物和方法。 在一个实施方案中，本发明提供了敲除动物，其基因组包含T细胞中海带状ECH相关蛋白1（KEAP1）的外显子2和外显子3的缺失。 在另一个实施方案中，治疗用AKI诊断的受试者的方法包括以下步骤：（a）从受试者中分离T细胞; （b）在分离的T细胞中激活Nrf2表达; 和（c）将T细胞给予受试者。

公开(公告)号：US09271479B2

公开(公告)日：2016-03-01

申请号：US14476626

申请日：2014-09-03

申请人： Hoffmann-La Roche Inc.

发明人： Javier Cote-Sierra ,  Antonio Iglesias ,  Claas Aiko Meyer

IPC分类号： A01K67/027 ,  G01N33/00 ,  C12N5/10 ,  C12N15/85 ,  A61K49/00 ,  G01N33/50

CPC分类号： A01K67/0276 ,  A01K67/0275 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0368 ,  A61K49/0008 ,  C12N15/85 ,  G01N33/502 ,  G01N33/5088 ,  G01N2500/10

摘要： The present invention relates to a non-human animal deficient in the N-terminal domain of the IL-33 gene. Also provided herein is the use of said non-human animal as an in vivo model of inflammatory diseases, especially with regard to screening methods for anti-inflammatory compounds, and methods for evaluating and optimizing the pharmacological properties of a given anti-inflammatory compound.

摘要翻译： 本发明涉及IL-33基因的N-末端结构域缺失的非人动物。 本文还提供了使用所述非人类动物作为炎性疾病的体内模型，特别是关于抗炎化合物的筛选方法，以及用于评估和优化给定抗炎化合物的药理学性质的方法。

公开(公告)号：US09127066B2

公开(公告)日：2015-09-08

申请号：US13087502

申请日：2011-04-15

申请人： Ming-Shi Chang

发明人： Ming-Shi Chang

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K31/7088 ,  A01K67/027 ,  C07K14/715

CPC分类号： C07K16/2866 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A61K31/7088 ,  C07K14/7155 ,  C07K2317/73 ,  C07K2317/76

摘要： Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

摘要翻译： 用抑制IL-20受体活性的药物治疗与由IL-20受体介导的信号传导途径相关的疾病（例如，骨质疏松症，肾衰竭或糖尿病性肾病），例如通过结合到中和IL-20受体的抗体 IL-20R1是抑制IL-20R1（抑制IL-20受体活性的小分子）或IL-19，IL-20或IL-24的显性失活突变体的表达的反义核酸。